Abraham Heifets, Atomwise CEO (Atomwise via website)

Ex­clu­sive: 'Faster is­n't bet­ter' — Atom­wise moves from part­ner­ships to pipeline with TYK2 drug

Atom­wise, one of the first star­tups to start pitch­ing an AI rev­o­lu­tion in drug dis­cov­ery just over a decade ago is now tak­ing a page from the tra­di­tion­al biotech play­book.

The San Fran­cis­co biotech is shift­ing its fo­cus from ink­ing hun­dreds of part­ner­ships that use its AI tech­nol­o­gy to de­vel­op­ing its own pipeline, start­ing with a TYK2 drug. Atom­wise has hired Neely Mozaf­far­i­an as its chief med­ical of­fi­cer, CEO Abra­ham Heifets told End­points News in an ex­clu­sive in­ter­view on his com­pa­ny’s fu­ture. Mozaf­far­i­an is an in­dus­try vet­er­an of Gen­tiBio, John­son & John­son, and Gilead Sci­ences.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.